Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies

COVID-19 is a clinical syndrome ranging from mild symptoms to severe pneumonia that often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung damage is driven by a surge in inflammatory cytokines [interleukin-6, interferon-γ, and granulocyte-monocyte stimulatin...

Full description

Bibliographic Details
Main Authors: Aldo Bonaventura, Alessandra Vecchié, Tisha S. Wang, Elinor Lee, Paul C. Cremer, Brenna Carey, Prabalini Rajendram, Kristin M. Hudock, Leslie Korbee, Benjamin W. Van Tassell, Lorenzo Dagna, Antonio Abbate
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Immunology
Subjects:
COVID-19
GM-CSF
IL-6
mavrilimumab
cytokine release syndrome
SARS-CoV-2
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01625/full

Similar Items

Similar Items